PPCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Propanc Biopharma Inc (PPCB) is not a good buy at the moment for a beginner investor with a long-term strategy. The company lacks positive financial performance, has no significant trading trends, no recent positive news, and no strong technical or proprietary trading signals to support a buy decision. Additionally, the stock's pre-market price is down 4.40%, and there are no clear catalysts for long-term growth.
The MACD is positive but contracting, RSI is neutral at 55.225, and moving averages are converging, indicating no strong trend. Key support levels are at 0.0959 and resistance at 0.159. The stock shows a 50% chance of minor losses (-0.83%) in the next day and limited upside potential in the next month (3.78%).
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Pre-market price is down 4.40%. Financial performance is weak, with no revenue growth and significant net income losses.
In 2026/Q2, revenue remained at 0 with no growth, net income increased to -$4,023,640 (up 835.33% YoY but still negative), EPS dropped significantly by -99.07% YoY to -0.3, and gross margin remained at 0.
No analyst ratings or price target changes available.
